Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy

Annette OrlethDepartment of Medical Oncology, University Hospital, Basel, Switzerland, ;Department of Biomedicine, University of Basel, Basel, Switzerland,

Christoph MamotDepartment of Biomedicine, University of Basel, Basel, Switzerland, ;Division of Medical Oncology, Cantonal Hospital, Aarau, Switzerland, and

Christoph RochlitzDepartment of Medical Oncology, University Hospital, Basel, Switzerland, ;Department of Biomedicine, University of Basel, Basel, Switzerland,

Reto RitschardDepartment of Medical Oncology, University Hospital, Basel, Switzerland, ;Department of Biomedicine, University of Basel, Basel, Switzerland,

Kari AlitaloBiomedicum Helsinki, Haartman Institute, University of Helsinki, Helsinki, Finland

Gerhard ChristoforiDepartment of Biomedicine, University of Basel, Basel, Switzerland,

Andreas WickiDepartment of Medical Oncology, University Hospital, Basel, Switzerland, ;Department of Biomedicine, University of Basel, Basel, Switzerland, Correspondence[email protected]

show all

Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy

Supplementary File S1 and Figures S1 and S2

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy

Supplementary File S1 and Figures S1 and S2

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date